Emerging exploration has focused on the cohort of C5aR1-blocking antibodies: vonlerolizumab. They offer unique strategies to inhibit this pathway, designed to manage disease in specific autoimmune states. Although https://miriamomdz904214.blog5.net/92308937/rg-7888-the-reviewing-study